ReCAP: Feasibility and Effectiveness of a Pilot Program to Facilitate Quality Improvement Learning in Oncology: Experience of the American Society of Clinical Oncology Quality Training Program.
OBJECTIVE
Studies have demonstrated that structured training programs can improve health professionals' skills in performing clinical care or research. We sought to develop and test a novel quality training program (QTP) tailored to oncology clinicians.


METHODS
The American Society of Clinical Oncology QTP consisted of three in-person learning sessions and four phases: prework, planning, implementation, and sustain and spread. We measured two primary outcomes: program feasibility and effectiveness. Feasibility was evaluated by recording participation. Effectiveness was measured using the Kirkpatrick model, which evaluates four outcomes: reaction, learning, behavior, and results. We collected qualitative feedback through a focus group of participants and mixed quantitative–qualitative results from a 6-month follow-up evaluation survey. Results are presented using descriptive statistics.


RESULTS
We received feedback from of 80% of participants who took part in 92% of in-person program days. QTP deliverables were completed by 100% of teams; none withdrew from the program. Regarding reaction, 100% of respondents expressed interest in actively contributing to future QTP courses. For learning, most teams continued to use the core methodology tools (eg, project charter, aims statements) after the program. Regarding behavior, when asked about intention to serve as a local quality improvement leader, a majority said they “definitely will” serve as: team leader on a specific project (75%), project champion or sponsor (75%), or teacher or trainer for others (64%). In evaluating outcomes, 50% reported applying learned methodology to new projects at their local institution.


CONCLUSIONS
We demonstrate one of the first feasible and effective training programs to facilitate quality improvement learning for oncology clinicians.
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA arif.kamal@duke.edu.
Arif H
AH
Kamal
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Doris
D
Quinn
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Timothy D
TD
Gilligan
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Barbara Corning
BC
Davis
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Carole K
CK
Dalby
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Jennifer
J
Bretsch
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Kristen K
KK
McNiff
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Joseph O
JO
Jacobson
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA arif.kamal@duke.edu.
Arif H
AH
Kamal
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Doris
D
Quinn
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Timothy D
TD
Gilligan
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Barbara
B
Corning Davis
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Carole K
CK
Dalby
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Jennifer
J
Bretsch
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Kristen K
KK
McNiff
Duke Cancer Institute, Durham, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; Cleveland Clinic, Cleveland, OH; Partners North Shore Medical Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; and American Society of Clinical Oncology, Alexandria, VA.
Joseph O
JO
Jacobson
D003695:Delivery of Health Care / Q000592:standards*; D004501:Education, Medical / Q000592:standards; D017144:Focus Groups; D019538:Health Care Surveys; D006801:Humans; D008495:Medical Oncology / Q000193:education* / Q000592:standards*; D011785:Quality Assurance, Health Care; D058996:Quality Improvement; D011787:Quality of Health Care